As it closes in on approval of its first U.S. biosimilar under the 351(k) pathway, Novartis AG’s Sandoz Inc. division is vowing not to repeat the pricing mistakes it made with the human growth hormone Omnitrope eight years ago.
Sandoz exec Mark McCamish told the FDA/CMS Summit in Washington, D.C., Dec. 11 that U.S. consumers, providers and payers will...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?